talquetamab
janssen
['monumental-1', 'multiple myeloma', 'talquetamab']
 incredible! just published nejm. myeloma patients treated w/ talquetamab orr &gt; 70% in phase 1/2 monumental-1 study. whopping 70.6% patients prior treated w/ car t-cell, 35.3% received prior bispecific antibody #ash22 click 
??Oncologist|??Cancer Researcher|President Ky @ASCO|MedSchool Professor @UofL|Faculty @ASCO @NCCN @OncoAlert|Advisor @MedScape @Onclive @Doximity|#MedTwitter